OverviewSuggest Edit

Scynexis is engaged in drug discovery, development and manufacturing projects in various areas and in manufacturing projects, such as antibacterials, antifungals, antiparasitics, antivirals, carbohydrates, central nervous system, controlled substances, kinases, natural products, neglected diseases, nuclear hormones, nucleosides, oncology, ophthalmology, pain, and prodrugs. The Company also provides contract research solutions, including medicinal chemistry, discovery biology, ADMET-PK, bioanalysis and analytical chemistry, process chemistry, and cGMP manufacturing.
HQJersey City, US
Employee Ratings2.6

Latest Updates

Employees (est.) (Mar 2020)27(+13%)
Revenue (FY, 2019)$121 K(-52%)
Share Price (Oct 2020)$5.1 (-1%)
Cybersecurity ratingAMore

Key People/Management at Scynexis

Marco Taglietti

Marco Taglietti

President and Chief Executive Officer, Director
Guy MacDonald

Guy MacDonald

Chairman of the Board
David Angulo

David Angulo

Chief Medical Officer
Armando Anido

Armando Anido

Eric Francois

Eric Francois

Chief Financial Officer
Steven C. Gilman

Steven C. Gilman

Show more

Scynexis Office Locations

Scynexis has an office in Jersey City
Jersey City, US (HQ)
1 Evertrust Plz
Show all (1)

Scynexis Financials and Metrics

Scynexis Revenue

Scynexis's revenue was reported to be $121 k in FY, 2019

Net income (Q2, 2020)


EBIT (Q2, 2020)


Market capitalization (16-Oct-2020)


Closing stock price (16-Oct-2020)


Cash (30-Jun-2020)



Scynexis's current market capitalization is $54.3 m.
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019



Cost of goods sold


Gross profit


Gross profit Margin, %

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020



Cost of goods sold


Gross profit


Gross profit Margin, %

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019



Accounts Receivable


Prepaid Expenses


Current Assets

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020



Accounts Receivable


Prepaid Expenses


Current Assets

USDQ1, 2014


-0.1 x


1.2 x

Financial Leverage

-0.1 x
Show all financial metrics

Scynexis Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Scynexis Online and Social Media Presence

Embed Graph

Scynexis Blogs

SCYNEXIS Commends the New York Times for its Reporting on Candida auris and Other Drug-Resistant Pathogens

Two articles published in the New York Times on April 6, 2019 highlight Candida auris and its significant global public health threat SCYNEXIS reaffirms its mission to develop ibrexafungerp as a novel antifungal to address serious infections caused by Candida auris and other resistant fungal pathoge…

SCYNEXIS's Ibrexafungerp Shows Favorable Clinical Activity in Resistant Fungal Infections, Including Candida auris Cases from the CARES Study, in Data to be Presented at the 29th ECCMID

Six presentations will provide additional evidence of the potent and broad antifungal activity of oral ibrexafungerp, including new clinical case studies from the CARES and FURI trials as well as promising preclinical data Case studies from the CARES trial, the first study of an investigational agen…

SCYNEXIS to Present Pre-clinical Data Supporting Prophylactic Use of Ibrexafungerp at Superbugs and Superdrugs 2019

Oral ibrexafungerp demonstrates potent antifungal activity against Pneumocystis in vivo Ibrexafungerp's broad spectrum activity and flexibility of oral administration highlight its potential utility as a prophylactic agent for immunocompromised patients JERSEY CITY, N.J., Feb. 28, 2019 /PRNewswir…

SCYNEXIS Announces Positive Interim Results from Phase 3 Open-Label FURI Study, Showing Oral Ibrexafungerp's Ability to Treat Refractory Fungal Infections and to Provide an Alternative to Long-Term IV Therapies

Analysis of first 20 patients confirms clinical antifungal activity of oral ibrexafungerp in patients with difficult-to-treat mucocutaneous and invasive fungal infections Positive findings support expanding the use of oral ibrexafungerp in the FURI study to build toward a future regulatory submissio…

SCYNEXIS Reports Third Quarter 2018 Financial Results and Provides Company Update

­JERSEY CITY, N.J., Nov. 13, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today reported financial results for the quarter ended September 30, 2018, and provided an update o…

SCYNEXIS Announces FDA Agreement with Company-Proposed Phase 3 Vulvovaginal Candidiasis Program for Oral Ibrexafungerp

Successful End-of-Phase 2 meeting provides clear regulatory path for both acute and recurrent VVC indications On target to initiate Phase 3 registration program in the fourth quarter of 2018 JERSEY CITY, N.J., Oct. 23, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company del…
Show more

Scynexis Frequently Asked Questions

  • When was Scynexis founded?

    Scynexis was founded in 1999.

  • Who are Scynexis key executives?

    Scynexis's key executives are Marco Taglietti, Guy MacDonald and David Angulo.

  • How many employees does Scynexis have?

    Scynexis has 27 employees.

  • What is Scynexis revenue?

    Latest Scynexis annual revenue is $121 k.

  • What is Scynexis revenue per employee?

    Latest Scynexis revenue per employee is $4.5 k.

  • Who are Scynexis competitors?

    Competitors of Scynexis include NGM Biopharmaceuticals, Solasia Pharma and Apotex Pharmachem.

  • Where is Scynexis headquarters?

    Scynexis headquarters is located at 1 Evertrust Plz, Jersey City.

  • Where are Scynexis offices?

    Scynexis has an office in Jersey City.

  • How many offices does Scynexis have?

    Scynexis has 1 office.